Innovent climbs as China regulator approves new drug application

Innovent Biologics

03/01/2025 02:24

** Shares of Innovent Biologics  1801.HK  climb 3.2% to
HK$36.65, on track for the biggest one-day pct rise since Dec. 9
    ** Innovent Biologics says China's National Medical Products
Administration (NMPA) has approved second New Drug Application
(NDA) of DOVBLERON, which is an oral ROS1 inhibitor for
treatment of adult patients with metastatic ROS1-positive
non-small cell lung cancer
    ** Says the NDA was accepted by the U.S. Food and Drug
Administration for priority review in December 2024
    ** Hang Seng Commerce & Industry Index  .HSNC  and
healthcare index  .HSCIH  both gain 0.4% while Hang Seng Index
 .HSI  adds 0.2%    

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))